2,31 $
21,42 %vorgestern
Nasdaq, 1. März, 22:06 Uhr
ISIN
IL0011651580
Symbol
PRFX
Berichte
Sektor
Industrie

PainReform Ltd Aktie News

Neutral
GlobeNewsWire
2 Tage alt
Reports continued enrollment in the second part of the Phase 3 clinical trial in bunionectomy
Neutral
GlobeNewsWire
etwa ein Monat alt
TEL AVIV, Israel, Jan. 22, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. ( Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that management will be participating at The Microcap Conference which is being held on January 30 - February 1, 2024 at Caesars Atlantic City Hotel & Casin...
Neutral
GlobeNewsWire
etwa 2 Monate alt
PRF-110 demonstrated superior formulation properties with respect to surface-tissue spreading PRF-110 demonstrated superior formulation properties with respect to surface-tissue spreading
Neutral
GlobeNewsWire
2 Monate alt
TEL AVIV, Israel, Dec. 26, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 467,896 ordinary shares, ...
Neutral
GlobeNewsWire
4 Monate alt
Reports enrollment of first patients for the second part of Phase 3 clinical trial in bunionectomy Reports enrollment of first patients for the second part of Phase 3 clinical trial in bunionectomy
Neutral
GlobeNewsWire
6 Monate alt
Targeting to commence second part of Phase 3 clinical trial in mid-Q4 2023 Trial completion and results expected in mid-2024 TEL AVIV, Israel, Sept. 11, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd.
Neutral
GlobeNewsWire
6 Monate alt
Professor Eli Hazum to Share Positive Safety and PK Data of PRF-110 from First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery Professor Eli Hazum to Share Positive Safety and PK Data of PRF-110 from First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery
Neutral
GlobeNewsWire
6 Monate alt
TEL AVIV, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform will be attending the H.C. Wainwright 25th Annual Global Investment Conference being held September 1...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen